BioCentury | Oct 19, 2015
Company News

Anthera, Zenyaku deal

...Zenyaku terminated a December 2014 deal with Anthera granting Zenyaku exclusive rights to develop and commercialize...
...original agreement, Anthera was eligible to receive up to $15 million in equity purchases by Zenyaku...
...time that the deal’s termination was announced, Zenyaku had purchased $9 million of Anthera shares. Zenyaku...
BioCentury | Jun 22, 2015
Clinical News

Blisibimod: Completed Phase III enrollment

...rights to the product from Amgen under a 2008 deal (see BioCentury, Jan. 14, 2008). Zenyaku...
...Anthera in Japan. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 2, 2015
Clinical News

Blisibimod: Phase III ongoing

...from Amgen under a 2008 deal (see BioCentury, Jan. 14, 2008). Last year, Anthera granted Zenyaku...
...blisibimod in Japan. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 31, 2014
Clinical News

Subcutaneous rituximab regulatory update

...IV rituximab is co-marketed as Rituxan by Chugai, which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 31, 2014
Clinical News

MabThera rituximab regulatory update

...by Chugai Pharmaceutical Co. Ltd. (Tokyo:4519, Tokyo, Japan), which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Jan 27, 2014
Clinical News

Subcutaneous rituximab regulatory update

...IV rituximab is co-marketed as Rituxan by Chugai, which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Dec 9, 2013
Company News

PharmAthene, Theraclone deal

...multiple options, including seeking a partner to move TCN-032 to the next stage of development. Zenyaku Kogyo Co. Ltd....
BioCentury | Oct 21, 2013
Clinical News

MabThera regulatory update

...by Chugai Pharmaceutical Co. Ltd. (Tokyo:4519, Tokyo, Japan), which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Sep 16, 2013
Clinical News

Human anti-M2e antibody: Phase IIa data

...aiming to get a government contract to fund the rest of the Phase II program. Zenyaku...
...which Theraclone will own 50% (see BioCentury, Aug. 5). Theraclone Sciences Inc. , Seattle, Wash. Zenyaku Kogyo Co. Ltd....
BioCentury | Sep 9, 2013
Product Development

Viral persistence

...particular look interesting" because potentially pandemic strains of flu have been emerging there. In 2010, Zenyaku Kogyo Co. Ltd....
...Sciences Inc. , Seattle, Wash. U.S. Department of Health & Human Services (HHS), Washington, D.C. Zenyaku Kogyo Co. Ltd....
Items per page:
1 - 10 of 197
BioCentury | Oct 19, 2015
Company News

Anthera, Zenyaku deal

...Zenyaku terminated a December 2014 deal with Anthera granting Zenyaku exclusive rights to develop and commercialize...
...original agreement, Anthera was eligible to receive up to $15 million in equity purchases by Zenyaku...
...time that the deal’s termination was announced, Zenyaku had purchased $9 million of Anthera shares. Zenyaku...
BioCentury | Jun 22, 2015
Clinical News

Blisibimod: Completed Phase III enrollment

...rights to the product from Amgen under a 2008 deal (see BioCentury, Jan. 14, 2008). Zenyaku...
...Anthera in Japan. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 2, 2015
Clinical News

Blisibimod: Phase III ongoing

...from Amgen under a 2008 deal (see BioCentury, Jan. 14, 2008). Last year, Anthera granted Zenyaku...
...blisibimod in Japan. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 31, 2014
Clinical News

Subcutaneous rituximab regulatory update

...IV rituximab is co-marketed as Rituxan by Chugai, which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Mar 31, 2014
Clinical News

MabThera rituximab regulatory update

...by Chugai Pharmaceutical Co. Ltd. (Tokyo:4519, Tokyo, Japan), which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Jan 27, 2014
Clinical News

Subcutaneous rituximab regulatory update

...IV rituximab is co-marketed as Rituxan by Chugai, which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Dec 9, 2013
Company News

PharmAthene, Theraclone deal

...multiple options, including seeking a partner to move TCN-032 to the next stage of development. Zenyaku Kogyo Co. Ltd....
BioCentury | Oct 21, 2013
Clinical News

MabThera regulatory update

...by Chugai Pharmaceutical Co. Ltd. (Tokyo:4519, Tokyo, Japan), which is majority owned by Roche, and Zenyaku Kogyo Co. Ltd....
BioCentury | Sep 16, 2013
Clinical News

Human anti-M2e antibody: Phase IIa data

...aiming to get a government contract to fund the rest of the Phase II program. Zenyaku...
...which Theraclone will own 50% (see BioCentury, Aug. 5). Theraclone Sciences Inc. , Seattle, Wash. Zenyaku Kogyo Co. Ltd....
BioCentury | Sep 9, 2013
Product Development

Viral persistence

...particular look interesting" because potentially pandemic strains of flu have been emerging there. In 2010, Zenyaku Kogyo Co. Ltd....
...Sciences Inc. , Seattle, Wash. U.S. Department of Health & Human Services (HHS), Washington, D.C. Zenyaku Kogyo Co. Ltd....
Items per page:
1 - 10 of 197